Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Vanderbilt
With the FDA approval of third line pembrolizumab for patients with SCLC, how would you select a candidate for pembrolizumab or nivolumab in the third line management of SCLC?
Related Questions
Would you consider using Elahere for patients with FOLR1-positive metastatic lung adenocarcinoma?
In ALK + metastatic NSCLC patients who have widespread progression on first line lorlatinib how do you determine your next line of therapy and what is your preference?
How would you consolidate a patient with primary refractory double hit lymphoma with secondary CNS involvement?
How do you approach duration of immunotherapy in patients with metastatic NSCLC?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
Is there a role for thiotepa-based auto transplant for consolidation in PCNSL if the patient had progression on both MTX and Ara-C?
How do you typically approach adjuvant therapy for a Masaoka stage IVa thymoma post-R0 resection?
Would you offer consolidative durvalumab after chemoRT for an isolated mediastinal recurrence of NSCLC that occurred during adjuvant pembrolizumab given for the initial lung cancer?
Would you provide vitamin B12 supplementation to a patient on pemetrexed therapy if their B12 levels are normal or high?
Do you tell your patients with epithelioid subtype mesothelioma following gross resection and adjuvant cis/pemetrexed that they have completed "curative intent" treatment?
